Well, that’s depressing.
I’ve seen multiple references online to “bloodbath.” The 190-member Nasdaq Biotechnology Index fell 3.4 percent on Day 1 of JP Morgan, the worst opening day of trading during the conference since 2001. Everything from tiny biotechs to large drugmakers were down.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A total aside, but was a Bloomberg anchor really unaware there is a such a thing as gene editing (1:50 in the video above)?
Just to drive home the point.
When you wake up at 3 am excited for lots of big, surprising #JPM16 Monday biotech news but instead get… pic.twitter.com/THDd05lgs8
— Adam Feuerstein (@adamfeuerstein) January 11, 2016
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
When things go your way for 6 straight years, your ability and skill set to deal with adversity is a touch Rusty. — Marc Cohodes (@AlderLaneeggs) January 10, 2016
Sounds right. Deal fest in San Francisco while $IBB takes an ugly 5% drop. Bon chance to you stock guys; off to a rough start at #JPM16 — John Carroll (@JohnCFierce) January 11, 2016
@adamfeuerstein so this is what a biotech bear market feels like. Ouch. The good and the bad blown up side by side. — Alex Berenson (@AlexBerenson) January 11, 2016
Wow, there will be serious drinking at #JPM16 tonight. Some may have already started. — Adam Feuerstein (@adamfeuerstein) January 11, 2016
Other notables
- Three early talking points (among others): Continued partnering and consolidation, innovative delivery approaches, and commitment to population health management.
- Day 1 of #JPM16: Liquid biopsies, rare diseases and off-the-record keynotes (San Francisco Business Journal)
- Keep an eye out for Alere: It did OK in the “biotech bloodbath” and it will expand its HIV testing platform.
- No shocker: No JP Morgan Conference Love for Ionis Pharmaceuticals Inc, Geron Corporation, and Medivation (Motley Fool)
And, of course, don’t forget all of MedCity News’ coverage on the conference. Twitterverse
“I think this year, revenue will be important” VC explaining their key 2016 thesis last night #overheardinUnionSq #jpm16 — coppedge (@coppedge) January 11, 2016
I’m going to start a tally of how many times I overhear Fire Marshall (7) and cattle yard (4) at #jpm16. Will keep you updated.
— Meghana Keshavan (@megkesh) January 11, 2016
I’m a little late in sharing, but fun all the same: “The Ultimate J.P. Morgan Shoe Strategy” from @CanaleComm #JPM16 https://t.co/NmTIAi4Q8H — Ian M Stone (@BiotechIan) January 11, 2016
All you #JPM16 ladies–how are your feet doing?? #sausagetoes
— Heidi Chokeir (@BiotechHeidi) January 12, 2016
Amazing first day! @startuphealth Festival #SUHfestival #JPM16 #startups #DigitalHealth #healthcare #changetheworld pic.twitter.com/u4iniThKRS — Wayne Kimmel (@waynekimmel) January 12, 2016
Photo: Flickr user Allan Donque
